Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.51 |
| ▸ | CDK2 | P24941 | 16/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.51 |
| ▸ | MGMT | P16455 | 6/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL6241914 | 0.84 | PDPK1 (0.59) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 2,6-Diaminopurine SCHEMBL10774603 | 0.84 | PDPK1 (0.59) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 2,6-Diaminopurine SCHEMBL2934952 | 0.84 | PDPK1 (0.59) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8068087 | 0.83 | CDK1 (0.47) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Ribose (Furanose) SCHEMBL291402 | 0.82 | PDPK1 (0.61) | CDK1CDK2 | |
| 6-Chloroguanine SCHEMBL7208346 | 0.82 | DPP4 (0.61) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8059232 | 0.82 | CDK1 (0.46) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL28389022 | 0.82 | ADORA3 (0.39) | MGMT | |
| Methylguanine SCHEMBL29903462 | 0.80 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL231097 | 0.80 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309833-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | CELLSIGHT TECHNOLOGIES INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4188453-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | Cellsight Technologies Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022026533-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | CELLSIGHT TECHNOLOGIES INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20150118157-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-9011817-B2 | Compounds and methods of making compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118157-A1 | Compounds and Methods of Making Compounds | MCL1, TOP2B, TOP1 | CDK1 127/4885CCNB1 405/4885CCNA2 289/4885 |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | MCL1, TOP1, TOP2B | CDK1 167/4885CCNB1 400/4885CCNA2 300/4885 |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | MCL1, TOP2B, TOP1 | CDK1 127/4885CCNB1 405/4885CCNA2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.